CA-4-based codrugs (or mutual prodrugs) have recently been demonstrated to improve the therapeutic profile of clinically used drugs such as doxorubicin, floxuridine and tegafur, and they have achieved targeted delivery of drugs to cancer tissues [114]. The gene discussed is CA4; the disease is cancer.